Ativação plaquetária em pacientes com COVID-longa com prejuízo cognitivo: um estudo longitudinal

Loading...
Thumbnail Image

Journal Title

Journal ISSN

Volume Title

Publisher

Universidade Federal de Juiz de Fora (UFJF)

DOI

Abstract

Long COVID is a condition characterized by the permanence of symptoms after the acute phase of COVID-19, for weeks, months and even years. Recent studies by our group have shown that patients with long-lasting COVID after a severe illness have platelet hyperactivation and hyperresponsiveness, but no study has shown that these mechanisms are present in patients with cognitive impairment after a mild acute illness. Therefore, our hypothesis is that platelet activation and hyperresponsiveness persist in patients with cognitive impairment after mild COVID-19. Thus, we conducted a prospective study to assess platelet activation at 198 (IQR 98.86-382.9), 376 (IQR 313.3-512), and 472 (IQR 421.8-568.8) days after acute infection in a cohort of patients classified as long COVID with cognitive impairment after evaluation by trained neuropsychologists. Two control groups were used in this study, the first composed of pre-pandemic individuals who had no contact with SARS-CoV-2 and the second composed of individuals who recovered from the acute phase without developing cognitive impairment. To investigate platelet activation, freshly isolated platelets were labeled for the platelet activation markers CD62p, CD63, PAC-1 and tissue factor (TF) and analyzed by flow cytometry. . In addition, to investigate platelet responsiveness, platelets were stimulated with thrombin and labeled with anti-CD62 and anti-CD63 monoclonal antibodies. Our results showed that patients have platelet hyperactivation with increased expression of CD62p and CD63 compared to the pre-pandemic group. In addition, platelets are hyper-responsive to thrombin in terms of CD62p and CD63 expression compared to the pre-pandemic group. When we evaluated the expression of CD62p over time, we observed a reduction, although still higher than the control group. These data show that patients with long COVID have platelet hyperactivation and hyperresponsiveness. In addition, the reduction in CD62p suggests patient recovery, but a longer period will be needed to confirm these data.

Description

Citation

Endorsement

Review

Supplemented By

Referenced By

Creative Commons license

Except where otherwise noted, this item's license is described as Acesso Embargado